Is the Poor Recovery of Commercial Recombinant Factors VIII and IX caused by Damage from Monoclonal Antibody Purification?

Thromb Haemost 2002; 88(04): 700-701
DOI: 10.1055/s-0037-1613285

Letters to the Editor

Schattauer GmbH

Edward Shanbrom

¹Santa Ana, California, USA

References
1 Stollar BD. Proteolytic antibodies against factor VIII in Hemophilia A. [Editorial]. N Engl J Med 2002; 346: 702-3.
2 Lacroix-Desmazes S, Bayry J, Misra N, Horn MP, Villard S, Pashov A, Stieltjes N, d’Oiron R, Saint-Remy J-M, Hoebeke J, Kazatchkine MD, Kaveri SV. The prevalence of proteolytic antibodies against factor VIII in Hemophilia A. N Engl J Med 2002; 346: 662-7.
3 Foster PA, Fulcher CA, Houghten RA, de Graaf SMahoney, Zimmerman TS. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine³⁵¹-serine³⁶⁵ of the factor VIII heavy chain. J Clin Invest 1988; 82: 123-8.